Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Choroidal Neovascularization Market Size From 2025 to 2034?
In recent times, the market size for choroidal neovascularization has experienced robust growth. It is projected to escalate from $3.88 billion in 2024 to $4.18 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%. Factors contributing to the growth in the past period include the surge in diseases related to a sedentary lifestyle, an increase in age-related macular degeneration cases, a higher number of retinal illness occurrences, an aging population, increasing expenses in eye care, and extensive efforts in education and screening.
The market for choroidal neovascularization is predicted to experience a significant surge in the coming years, set to expand to$5.59 billion by 2029 with a compound annual growth rate (CAGR) of 7.5%. The augmented development during the forecast period can be linked to factors like heightened patient consciousness, elevated usage of optical coherence tomography angiography, increased need for minimally invasive processes, positive reimbursement schemes, and an aging population. The forecast period will also see key trends such as the rise in intravitreal anti-vascular endothelial (VEGF) treatments, the introduction of new gene therapies, advancements in gene therapy approaches, the utilization of telemedicine, the formulation of combination therapies, and the creation of customized treatment plans.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp
What Are the Core Growth Drivers Propelling the Choroidal Neovascularization Market Forward?
Expectations for the choroidal neovascularization (CNV) market’s advancement are fueled by escalating instances of age-related macular degeneration (AMD). AMD is an ocular disorder that progressively impairs the macula, leading to loss of central vision, primarily amongst elderly adults. The surge in AMD rates can be attributed to an aging population, prolonged lifespan, transformations in lifestyle, genetic elements, and greater exposure to environmental hazards. CNV aids patients suffering from AMD by facilitating the development of wet AMD, which is characterized by the growth of irregular blood vessels beneath the retina that lead to a decline in vision and necessitate complex treatments such as anti-VEGF therapy. This therapy serves to manage CNV and decelerate the progression of AMD, thereby preserving central vision in affected individuals. For instance, the National Institutes of Health, a government agency based in the US, reported in September 2022 that by 2040, AMD cases may rise to 300 million and by 2050, 5.4 million Americans might be impacted. Therefore, the escalating instances of AMD are contributing to the growth of the CNV market.
What Segment Types Define the Choroidal Neovascularization Market Structure?
The choroidal neovascularizationmarket covered in this report is segmented –
1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications
3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral
4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers
Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy; Combination Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Choroidal Neovascularization Market?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theChoroidal Neovascularization Industry Evolution?
Leading organizations in the choroidal neovascularization market are directing their efforts on the development of novel therapies, such as photodynamic therapy, targeting the provision of exact and effective treatment choices to eye care professionals, thereby leading to improved patient results and streamlined treatment. Photodynamic therapy (PDT) is a medicinal procedure utilizing a photosensitizing agent activated via light to eliminate unusual or cancerous cells. In a practical example, Bausch & Lomb, a Canadian healthcare enterprise, in collaboration with Modulight, a biomedical firm based in Finland, announced in February 2023, the approval of ML6710i photodynamic laser by the Food and Drug Administration, a US federal agency. This treatment approval is specific to its application in conjunction with Bausch + Lomb’s VISUDYNE therapy, a treatment designed specifically for choroidal neovascularization resulting from age-related macular degeneration (AMD). This state-of-the-art portable ophthalmic laser delivers a focused method for addressing abnormal eye blood vessels, aiding in the prevention of further disease advancement and the preservation of visual acuity.
View the full report here:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report
What Is the Definition of the Choroidal Neovascularization Market?
Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage the retinal tissues, leading to vision distortion or loss.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model